Quick reference manual for silicon integrated circuits technology / 由 Beadle, W. E., Tsai, J. C. C., Plummer, R. D.

Clinical development of new drug-radiotherapy combinations. 由 Sharma, R, Plummer, R, Stock, J, Greenhalgh, T, Hawkins, M, NCRI CTRad Academia-Pharma Joint Working Group

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours 由 Wilson, R, Jeffry Evans, T, Middleton, M, Molife, L, Spicer, J, Dieras, V, Roxburgh, P, Giordano, H, Jaw-Tsai, S, Goble, S, Plummer, R

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation... 由 Plummer, R, Lorigan, P, Steven, N, Scott, L, Middleton, M, Wilson, R, Mulligan, E, Curtin, N, Wang, D, Dewji, R, Abbattista, A, Gallo, J, Calvert, H

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. 由 Harrington, K, Billingham, L, Brunner, T, Burnet, N, Chan, C, Hoskin, P, Mackay, R, Maughan, T, Macdougall, J, Mckenna, W, Nutting, C, Oliver, A, Plummer, R, Stratford, I, Illidge, T

Radiotherapy research priorities for the UK. 由 Maughan, T, Illidge, T, Hoskin, P, Mckenna, W, Brunner, T, Stratford, I, Harrington, K, Plummer, R, Billingham, L, Nutting, C, Burnet, N, Mackay, R, Oliver, A, Young, C, Chan, C

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. 由 Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers 由 Harrington, K, Billingham, L, Brunner, T, Burnet, N, Chan, C, Hoskin, P, MacKay, R, Maughan, T, MacDougall, J, Mckenna, W, Nutting, C, Oliver, A, Plummer, R, Stratford, I, Illidge, T

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... 由 Boss, D, Schwartz, G, Middleton, MR, Amakye, D, Swaisland, H, Midgley, R, Ranson, M, Danson, S, Calvert, H, Plummer, R, Morris, C, Carvajal, R, Chirieac, L, Schellens, J, Shapiro, G

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma 由 Gupta, A, Love, S, Schuh, A, Collins, L, Thomason, A, Asher, R, Lisle, R, Churchman, M, Shanyinde, M, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Larkin, J, Middleton, MR

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib 由 Mateo, J, Moreno, V, Gupta, A, Kaye, S, Dean, E, Middleton, M, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, L

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. 由 Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L, Calvert, H

A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases 由 Plummer R, Greystoke A, Naylor G, Sarker D, Anam ANMK, Prenen H, Teuwen LA, Van Cutsem E, Dekervel J, Haugk B, Ness T, Bhoi S, Jensen M, Morris T, Baumann P, Sjögren N, Tunblad K, Wallberg H, Öberg F, Evans TRJ

获取全文

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors 由 Soria, J, Gan, H, Blagden, S, Plummer, R, Arkenau, H, Ranson, M, Evans, T, Zalcman, G, Bahleda, R, Hollebecque, A, Lemech, C, Dean, E, Brown, J, Gibson, D, Peddareddigari, V, Murray, S, Nebot, N, Mazumdar, J, Swartz, L, Auger, K, Fleming, R, Singh, R, Millward, M

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. 由 Leach, M, Morgan, B, Tofts, P, Buckley, D, Huang, W, Horsfield, M, Chenevert, T, Collins, D, Jackson, A, Lomas, D, Whitcher, B, Clarke, L, Plummer, R, Judson, I, Jones, R, Alonzi, R, Brunner, T, Koh, D, Murphy, P, Waterton, J, Parker, G, Graves, M, Scheenen, T, Redpath, T, Orton, M

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients 由 S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P